Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies

Sanjay Kulkarni, Abhijeet Pandey, Srinivas Mutalik

Research output: Contribution to journalReview article

Abstract

Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific release of drugs. We provide insight into alternative modes of therapy, such as phototherapy, gene therapy, dendritic cell (DC) therapy, and radiotherapy, highlighting recent advances in the treatment of HMs.

Original languageEnglish
JournalDrug Discovery Today
DOIs
Publication statusAccepted/In press - 01-01-2019

Fingerprint

Hematologic Neoplasms
Peptide Nucleic Acids
Phototherapy
Golgi Apparatus
Complementary Therapies
Cell- and Tissue-Based Therapy
Genetic Therapy
Nanoparticles
Dendritic Cells
Mitochondria
Radiotherapy
Therapeutics
Metals
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

@article{80b93965d13e4f0bad9612d77c80ab61,
title = "Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies",
abstract = "Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific release of drugs. We provide insight into alternative modes of therapy, such as phototherapy, gene therapy, dendritic cell (DC) therapy, and radiotherapy, highlighting recent advances in the treatment of HMs.",
author = "Sanjay Kulkarni and Abhijeet Pandey and Srinivas Mutalik",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.drudis.2019.10.001",
language = "English",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",

}

Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies. / Kulkarni, Sanjay; Pandey, Abhijeet; Mutalik, Srinivas.

In: Drug Discovery Today, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies

AU - Kulkarni, Sanjay

AU - Pandey, Abhijeet

AU - Mutalik, Srinivas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific release of drugs. We provide insight into alternative modes of therapy, such as phototherapy, gene therapy, dendritic cell (DC) therapy, and radiotherapy, highlighting recent advances in the treatment of HMs.

AB - Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific release of drugs. We provide insight into alternative modes of therapy, such as phototherapy, gene therapy, dendritic cell (DC) therapy, and radiotherapy, highlighting recent advances in the treatment of HMs.

UR - http://www.scopus.com/inward/record.url?scp=85073717347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073717347&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.10.001

DO - 10.1016/j.drudis.2019.10.001

M3 - Review article

C2 - 31614201

AN - SCOPUS:85073717347

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -